Key result
This editorial discusses strategies such as intracoronary abciximab to prevent and treat microvascular dysfunction and improve primary PCI outcomes in patients with STEMI.
Why the study?
Does intracoronary administration of abciximab improve microvascular dysfunction in patients with STEMI undergoing primary PCI?
Does intracoronary administration of abciximab improve microvascular dysfunction in patients with STEMI undergoing primary PCI?
This editorial discusses the role of intracoronary abciximab in preventing and treating microvascular dysfunction after primary PCI for STEMI.
P rimary percutaneous coronary intervention (PCI) is nowthe preferred method of treating patients with STelevation myocardial infarction (STEMI).Despite restoration of epicardial flow, microvascular obstruction may persist after primary PCI as a result of both atheromatous and thrombotic embolization, neutrophil plugging, edema, and vasospasm.[1][2][3] Therefore, studies such as the one by Thiele et al 4 in this issue of Circulation that focus on the prevention and treatment of microvascular dysfunction are informative with respect to the means to improve the primary PCI strategy.
No takes yet. Share an insight, caveat, or question.
Gibson et al. (2008) conducted an editorial in ST-Elevation Myocardial Infarction. Intracoronary Administration of Abciximab was evaluated. This editorial discusses strategies such as intracoronary abciximab to prevent and treat microvascular dysfunction and improve primary PCI outcomes in patients with STEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: